Amgen Inc. $AMGN Shares Sold by ProVise Management Group LLC

ProVise Management Group LLC trimmed its holdings in shares of Amgen Inc. (NASDAQ:AMGN – Free Report) by 8.1% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 15,152 shares of the medical research company’s stock after selling 1,344 shares during the period. ProVise Management Group LLC’s holdings in Amgen were worth $6,387,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also added to or reduced their stakes in the company. State Street Corp raised its holdings in shares of Amgen by 38.2% in the 2nd quarter. State Street Corp now owns 42,205,243 shares of the medical research company’s stock valued at $15,283,363,000 after purchasing an additional 11,656,755 shares in the last quarter. Bank of America Corp DE bought a new position in shares of Amgen during the second quarter valued at approximately $1,831,903,000. Wellington Management Group LLP raised its stake in Amgen by 1,102.7% in the second quarter. Wellington Management Group LLP now owns 2,742,271 shares of the medical research company’s stock worth $993,031,000 after buying an additional 2,514,254 shares in the last quarter. BlackRock Inc. lifted its holdings in Amgen by 4.8% during the second quarter. BlackRock Inc. now owns 49,362,016 shares of the medical research company’s stock worth $17,874,974,000 after buying an additional 2,261,544 shares during the period. Finally, Assenagon Asset Management S.A. lifted its holdings in Amgen by 702.8% during the third quarter. Assenagon Asset Management S.A. now owns 1,535,257 shares of the medical research company’s stock worth $647,126,000 after buying an additional 1,344,010 shares during the period. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Analysts Set New Price Targets

AMGN has been the topic of several recent research reports. Truist Financial increased their target price on Amgen from $380.00 to $398.00 and gave the company a “hold” rating in a research report on Wednesday, November 4th. JPMorgan Chase & Co. boosted their price target on Amgen from $350.00 to $425.00 and gave the stock a “neutral” rating in a research report on Wednesday, November 4th. TD Cowen boosted their price target on Amgen from $452.00 to $531.00 and gave the stock a “buy” rating in a research report on Wednesday, November 4th. Argus upped their price objective on Amgen from $460.00 to $515.00 and gave the stock a “buy” rating in a research note on Thursday. Finally, Bank of America raised their price objective on Amgen from $312.00 to $317.00 and gave the company an “underperform” rating in a research report on Wednesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, eleven have given a Buy rating, eighteen have given a Hold rating and three have issued a Sell rating to the company. Based on data from MarketBeat, Amgen has a consensus rating of “Hold” and an average target price of $424.66.

Get Our Latest Analysis on AMGN

Amgen Stock Performance

NASDAQ AMGN opened at $465.67 on Monday. The company has a quick ratio of 1.20, a current ratio of 1.48 and a debt-to-equity ratio of 3.60. The firm has a market cap of $251.89 billion, a PE ratio of 27.01, a price-to-earnings-growth ratio of 3.24 and a beta of 0.43. The company has a 50 day moving average price of $425.31 and a 200 day moving average price of $381.17. Amgen Inc. has a 52 week low of $312.39 and a 52 week high of $483.99.

Amgen (NASDAQ:AMGN – Get Free Report) last posted its earnings results on Tuesday, November 3rd. The medical research company reported $6.45 EPS for the quarter, beating analysts’ consensus estimates of $5.79 by $0.66. The company had revenue of $10.37 billion during the quarter, compared to analysts’ expectations of $10.07 billion. Amgen had a net margin of 24.14% and a return on equity of 114.99%. Amgen’s revenue for the quarter was up 8.5% compared to the same quarter last year. During the same quarter in the prior year, the company posted $5.64 earnings per share. As a group, sell-side analysts forecast that Amgen Inc. will post 23.37 EPS for the current fiscal year.

Amgen Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Friday, December 11th. Shareholders of record on Friday, November 20th will be issued a $2.52 dividend. This represents a $10.08 annualized dividend and a yield of 2.2%. The ex-dividend date of this dividend is Friday, November 20th. Amgen’s payout ratio is currently 58.47%.

Amgen Company Profile

(Free Report)

Amgen is a biotechnology company that discovers, develops, manufactures and commercializes medicines for serious illnesses. Its research and product portfolio span areas including cancer, cardiovascular disease, inflammation, bone health and rare diseases. The company’s medicines include Enbrel, Prolia, Xgeva and Repatha. Amgen serves patients and healthcare providers in the United States and markets its products internationally. Founded in 1980 and headquartered in Thousand Oaks, California, Amgen is led by Robert A. Bradway, who has served as its chief executive officer since 2012.

Featured Stories

Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Receive News & Ratings for Amgen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amgen and related companies with MarketBeat.com's FREE daily email newsletter.